Explore

Trendline Trendline
Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers
Trendline Trendline
AN2 Therapeutics Reports Q1 2026 Financial Results and Advances Clinical Programs

AN2 Therapeutics Reports Q1 2026 Financial Results and Advances Clinical Programs

AN2 Therapeutics Reports Q1 2026 Financial Results and Advances Clinical Programs
Trendline Trendline
Thryv Therapeutics to Present SGK1 Inhibitor Progress at Major Healthcare Conferences

Thryv Therapeutics to Present SGK1 Inhibitor Progress at Major Healthcare Conferences

Thryv Therapeutics to Present SGK1 Inhibitor Progress at Major Healthcare Conferences
Trendline Trendline
AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials
Trendline Trendline
Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases

Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases

Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development
Trendline Trendline
JCR Pharmaceuticals to Showcase Gene Therapy Innovations at ASGCT Meeting in Boston

JCR Pharmaceuticals to Showcase Gene Therapy Innovations at ASGCT Meeting in Boston

JCR Pharmaceuticals to Showcase Gene Therapy Innovations at ASGCT Meeting in Boston
Trendline Trendline
AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics

AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics

AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics
Trendline Trendline
Turn Therapeutics Advances GX-03 in Phase 2 Trial for Atopic Dermatitis with Financial Backing

Turn Therapeutics Advances GX-03 in Phase 2 Trial for Atopic Dermatitis with Financial Backing

Turn Therapeutics Advances GX-03 in Phase 2 Trial for Atopic Dermatitis with Financial Backing
Trendline Trendline
Enterprise Therapeutics Achieves Key Milestone in Cystic Fibrosis Treatment with ETD001

Enterprise Therapeutics Achieves Key Milestone in Cystic Fibrosis Treatment with ETD001

Enterprise Therapeutics Achieves Key Milestone in Cystic Fibrosis Treatment with ETD001
Trendline Trendline
Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302
Trendline Trendline
BeOne Medicines Honored as 'Outstanding Global Oncology Company' for Advancements in Cancer Therapies

BeOne Medicines Honored as 'Outstanding Global Oncology Company' for Advancements in Cancer Therapies

BeOne Medicines Honored as 'Outstanding Global Oncology Company' for Advancements in Cancer Therapies